- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02904226
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (ICONIC)
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Sarah Cannon Research Institute at HealthONE
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown Lombardi Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago Medicine Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute at TriStar Health
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas - MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- South Texas Accelerated Research Therapeutics, LLC
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be willing and able to participate and comply with all trial requirements and able to provide signed and dated informed consent prior to initiation of any trial procedures
- Evaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohort
- Male or Female ≥ 18 years of age
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. Subjects with ECOG 2 may be considered for enrollment in Parts C, D, F, and H if approved by Medical Monitor
- Have a predicted life expectancy of ≥ 3 months
- Have laboratory values (obtained ≤ 28 days prior to first infusion day) in accordance with the study protocol
- If medical history of the following, case should be reviewed by the Medical Monitor: prior biliary tract disorders (as based on Hepatobiliary SOC high level terms of: obstructive bile duct disorders, hepatic vascular disorders, structural and other bile duct disorders) or portal hypertension and/or hepatic vascular disorders
- Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of each dose of JTX-2011
- WOCBP and males with partners of child-bearing potential must agree to use adequate birth control throughout their participation and for 5 months following the last study treatment
Exclusion Criteria:
- Receiving concurrent anti-cancer treatment (excluding radiation therapy), either approved or investigational
- Have refused standard therapy
Have received anti-cancer therapies listed below within the specified timeframe, or who have ongoing toxicity from prior therapy > Grade 1 according to the Common Terminology for Adverse Events (CTCAE). Exceptions to this are: > Grade 1 toxicities which in the opinion of the Investigator should not exclude the subject (e.g. alopecia, Grade 2 neuropathy, hypo- or hyperthyroidism or other endocrinopathies that are well-controlled with hormone replacement) and are approved by the Medical Monitor.
- Have received biologic therapy, including immunotherapy, < 28 days prior to C1D1;
- Have received CAR-T therapy;
- Have received chemotherapy < 21 days prior to C1D1, or < 42 days for mitomycin or nitrosoureas;
- Have received targeted small molecule therapy < 14 days prior to C1D1;
- Have undergone organ transplantation including allogeneic or autologous stem-cell transplantation, at any time;
- Have undergone a major surgery (excluding minor procedures, e.g. placement of vascular access, biopsy, etc.) < 6 months prior to the first day of study treatment, C1D1
- Have a history of intolerance, hypersensitivity, or treatment discontinuation due to severe immune adverse events on prior immunotherapy, or documented presence of neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects who discontinued prior immunotherapies for immune-related adverse events that are well-controlled with appropriate treatment may be enrolled if approved by the Medical Monitor.
- Have a diagnosis of immunodeficiency, either primary or acquired, or treatment with systemic steroids or any other form of immunosuppressive therapy within 7 days prior to C1D1. Exception: inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease as well as a one-time dose of immunosuppressive agents used prophylactically for contrast allergies
- Have any active disease requiring systemic immunosuppressive treatment
- Have known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
- Are symptomatic or have uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation (brain metastases that are stable and asymptomatic, either treated or untreated, will be allowed)
- Have current second malignancy at other sites, which requires treatment, or in the judgement of the Investigator, may require treatment within the next year. Concurrent malignancies that do not require treatment and are clinically stable are allowed. A past history of other malignancies is allowed as long as the subject is not receiving specific treatment other than hormonal therapy, and, in the judgement of the Investigator, is unlikely to have a recurrence.
- Have active and clinically relevant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required)
- Have received live vaccines within past 30 days (inactivated vaccines are allowed; seasonal vaccines should be up to date prior to first infusion day)
- Women who are pregnant or breastfeeding
- Have experienced symptomatic cardiac disease that is unresponsive to surgical or medical management
- Have any medical or social condition that, in the opinion of the Investigator, might place a subject at increased risk, affect compliance, or confound safety or other clinical trial data interpretation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part A (JTX-2011)
Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
|
Specified dose on specified days
Other Names:
|
|
Experimental: Part B (JTX-2011 + nivolumab)
Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Part C (JTX-2011)
Phase 2 expansion of JTX-2011 by IV infusion
|
Specified dose on specified days
Other Names:
|
|
Experimental: Part D (JTX-2011 + nivolumab)
Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Part E (JTX-2011 + ipilimumab)
Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Part F (JTX-2011 + ipilimumab)
Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Part G (JTX-2011 + pembrolizumab)
Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Part H (JTX-2011 + pembrolizumab)
Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with an adverse event occurring from the time of informed consent until resolution or new therapy initiated or for 28 days post final dose if no new therapy is initiated
|
46.3 months
|
|
Number of Participants With Grade 5 (Fatal) Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with Grade 5 (fatal) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
46.3 months
|
|
Number of Participants With Grade 4 (Life Threatening) Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with Grade 4 (life threatening) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
46.3 months
|
|
Number of Participants With Grade 3 (Sever) Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with Grade 3 (severe) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03."
|
46.3 months
|
|
Number of Participants With Grade 2 (Moderate) Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with Grade 2 (moderate) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
|
46.3 months
|
|
Number of Participants With Grade 1 (Mild) Treatment Emergent Adverse Events (TEAE)
Time Frame: 46.3 months
|
Number of participants with Grade 1 (mild) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
|
46.3 months
|
|
Number of Participants With Dose Limiting Toxicities
Time Frame: 33 months
|
Number of participants with at least one dose limiting toxicity (DLT)
|
33 months
|
|
Overall Response Rate
Time Frame: 46.5 months
|
Overall response rate (ORR) is defined as the proportion of subjects with a Best Overall Response characterized as either a Complete Response (CR) or Partial Response (PR) as defined by RECISTv1.1 guidelines based on investigator's review
|
46.5 months
|
|
Disease Control Rate
Time Frame: 46.5 months
|
Disease Control Rate: Percent Subjects with confirmed Complete Response + confirmed Partial Response + BoR of SD (or unconfirmed complete response or partial response lasting at least 53 days from the date of first dose)
|
46.5 months
|
|
Progression Free Survival
Time Frame: 46.5 months
|
Progression free survival, as determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
|
46.5 months
|
|
6 Month Landmark Progression Free Survival
Time Frame: 46.5 months
|
Percentage of patients that are progression free at 6 months, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period.
This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.
|
46.5 months
|
|
12 Month Landmark Progression Free Survival
Time Frame: 46.5 months
|
Percentage of patients that are progression free at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period.
This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.
|
46.5 months
|
|
Landmark Overall Survival at 6 Months
Time Frame: 46.5 months
|
Percentage of patients that are alive at 6 month, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period.
This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.
|
46.5 months
|
|
Landmark Overall Survival at 12 Months
Time Frame: 46.5 months
|
Percentage of patients that are alive at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period.
This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.
|
46.5 months
|
|
Overall Survival
Time Frame: 46.5 months
|
The time from first dose date to the date of death for any cause
|
46.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Stew Kroll, Jounce Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JTX-2011-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.